Forty Leading Organizations, Including 11 of the 20 Largest Dairy Companies in the World, Among First to Support New Global “Pathways to Dairy Net Zero” Climate Initiative
22.9.2021 10:00:00 EEST | Business Wire | Press release
Pathways to Dairy Net Zero, a ground-breaking new climate initiative, is launching today during Climate Week and just prior to the United Nations (UN) Food Systems Summit. Forty leading organizations, including 11 of the 20 largest dairy companies in the world, have already declared their support for the effort. Collectively, these supporters represent approximately 30 percent of total milk production worldwide.
The new climate initiative demonstrates the global dairy sector’s commitment to reducing GHG emissions while continuing to produce nutritious foods for six billion people and provide for the livelihoods of one billion people.
“Pathways to Dairy Net Zero will accelerate climate efforts already underway and drive further necessary action to reduce dairy’s emissions over the next decades. The dairy sector has a lot to offer to lead this transition,” said Hein Schumacher, Chief Executive Officer of Royal FrieslandCampina and Chairman of Global Dairy Platform.
“Mengniu is proud to join the global dairy sector in uniting behind this effort, the first of its kind in agriculture, because we must all do our part to meet this worldwide climate challenge,” said Minfang (Jeffrey) Lu, Chief Executive Officer and Executive Director of China Mengniu Dairy Company.
The initiative is underpinned by six key principles:
- Mitigation. Continuing to improve production and process efficiency to further reduce the GHG emissions intensity of milk and dairy products.
- Greenhouse gas removals. Enhancing production practices that protect carbon sinks (soil, forests, grass, peatlands) and complement natural ecosystems.
- Avoidance and adaptation. Improving practices such as feed, manure, fertilizer and energy management.
- Insets and offsets. Identify and implement alternative, credible reduction options.
- Measurement and monitoring. Measuring greenhouse gas emissions to plan mitigation and monitor progress.
- Overall support. Promoting the global initiative and emphasizing the dairy sector’s climate ambition.
Identifying and Clarifying Plausible Mitigation Options
A multi-stakeholder group of organizations, including the global dairy sector and representatives from the scientific and research communities, are working together to develop science-based methodologies, tools and pathways that work for every dairy system.
Research is underway to identify where positive climate change action is possible. The study is led by Scotland’s Rural College and the New Zealand Agricultural Greenhouse Gas Research Centre, research institutions from two of the Global Research Alliance on Agricultural Greenhouse Gases’ 65 member countries, backed up by data and analysis from the UN Food and Agriculture Organization.
Initial research found that the dairy sector already has the means to reduce a significant proportion of emissions - up to 40 percent in some systems - by improving productivity and resource use efficiency.1
Researchers are identifying plausible GHG mitigation pathways for different dairy systems globally, in particular methane reduction. The latest Intergovernmental Panel on Climate Change (IPCC) report2 reaffirmed that the main GHG challenge is the reduction of carbon dioxide, which remains in the atmosphere for centuries. The report also identified reductions in methane, a potent but short-lived climate pollutant that lasts only about 12 years in the atmosphere, as an immediate opportunity to address global warming.
Organizations Already Supporting Pathways to Dairy Net Zero
The list so far includes: Nestle, Dairy Farmers of America, Danone, Fonterra Co-operative Group, Royal FrieslandCampina, Arla Foods, China Mengniu Dairy Company, Saputo, Meiji Holdings, Savencia Fromage & Dairy, Agropur Dairy Cooperative, Ace Farming Company, Agri Networking Tools, Australian Dairy Products Federation, Brazzale, Dairy Australia, Dairy Connect, Dairy Farmers of Canada, Dairy Management Inc., Dairy UK, Dutch Dairy Association, First Milk, FOSS Analytics, Glanbia, Granja Tepeyac, Innovation Center for U.S. Dairy, International Dairy Foods Association, La Vida Lactea, Land O’Lakes, Lekhanath Dairy International, Leprino Foods Company, Livestock Improvement Corporation, Megmilk Snow Brand, Morinaga Milk Industry, National Dairy Development Board (India), National Milk Producers Federation (U.S.), Palmhouse Dairies, Pioneer Natural Capital, Royal DSM, U.S. Dairy Export Council.
For more information, or to join Pathways to Dairy Net Zero, visit: www.pathwaystodairynetzero.org.
About Pathways to Dairy Net Zero
Pathways to Dairy Net Zero is a vibrant, growing movement, the first of its kind in the world. It brings together dairy systems of every size and type, including organizations throughout the dairy supply chain.
Partners include: Global Dairy Platform, International Dairy Federation, Sustainable Agriculture Initiative Platform, International Livestock Research Institute, Dairy Sustainability Framework and IFCN Dairy Research Network.
The Global Research Alliance on Agricultural Greenhouse Gases is a knowledge partner.
References
- Gerber PJ, Steinfeld H, Henderson B, et al. 2013. Tackling climate change through livestock – A global assessment of emissions and mitigation opportunities. Food and Agriculture Organization of the United Nations (FAO), Rome. Available at: http://www.fao.org/3/i3437e/i3437e.pdf [Accessed July 2021].
- IPCC, 2021: Climate Change 2021: The Physical Science Basis. Contribution of Working Group I to the Sixth Assessment Report of the Intergovernmental Panel on Climate Change [Masson-Delmotte, V., P. Zhai, A. Pirani, S. L. Connors, C. Péan, S. Berger, N. Caud, Y. Chen, L. Goldfarb, M. I. Gomis, M. Huang, K. Leitzell, E. Lonnoy, J. B. R. Matthews, T. K. Maycock, T. Waterfield, O. Yelekçi, R. Yu and B. Zhou (eds.)]. Cambridge University Press. In Press.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210922005358/en/
Contact information
Kevin Burkum, Director of Communications
+1 847-627-3387
Kevin.Burkum@GlobalDairyPlatform.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
